News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Poirson Allen
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/21/2023 |
4
| Poirson Allen (SVP Bus. and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Paid exercise price by delivering 308 shares
@ $8.46, valued at
$2.6k
Paid exercise price by delivering 975 shares
@ $8.46, valued at
$8.2k
Exercised 790 restricted stock units
@ $0 Exercised 2,503 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Poirson Allen (SVP Bus. and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Paid exercise price by delivering 308 shares
@ $6.69, valued at
$2.1k
Paid exercise price by delivering 651 shares
@ $6.69, valued at
$4.4k
Exercised 790 restricted stock units
@ $0 Exercised 1,669 restricted stock units
@ $0 |
|
03/07/2023 |
4
| Poirson Allen (SVP Bus. and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Granted 60,541 options to buy
@ $10.61, valued at
$642.3k
Granted 40,056 restricted stock units
@ $0 |
|
02/23/2023 |
4
| Poirson Allen (SVP Bus. and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Paid exercise price by delivering 308 shares
@ $10.97, valued at
$3.4k
Exercised 790 restricted stock units
@ $0 |
|
11/22/2022 |
4
| Poirson Allen (SVP Bus. and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Paid exercise price by delivering 308 shares
@ $14.75, valued at
$4.5k
Exercised 790 restricted stock units
@ $0 |
|
08/19/2022 |
4
| Poirson Allen (SVP Marketing and Corp. Dev.) has filed a Form 4 on Cytek Biosciences, Inc.
Txns:
| Paid exercise price by delivering 308 shares
@ $14.06, valued at
$4.3k
Exercised 790 restricted stock units
@ $0 |
|
05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/27/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/26/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|